Eloralintide vs Retatrutide
Eloralintide (LY3841136) and Retatrutide (LY3437943) are both investigational compounds, but they represent completely different bets on the next generation of obesity pharmacology. Retatrutide adds a third receptor (glucagon) to the incretin backbone; Eloralintide brings in the entirely separate amylin axis. This page compares them as research compounds.
Eloralintide 10mg is booked in for a full-panel independent test at Vanguard Laboratory: purity, quantity, endotoxins and sterility. Results from late October, in the COA Library.
| Eloralintide | Retatrutide | |
|---|---|---|
| Development code | LY3841136 | LY3437943 |
| Receptor targets | Amylin receptors (selective) | GLP-1, GIP, glucagon (triple) |
| Mechanism family | Amylin analogue | Incretin + glucagon agonist |
| Development stage | ENLIGHTEN Phase 3 | TRIUMPH Phase 3 |
| Peak Phase 2 body-weight reduction | 9.5% to 20.1% at 48 weeks | 24.2% at 12mg by 48 weeks |
| Phase 3 result | Not yet reported | TRIUMPH-1: 17.6% to 25.0% at 80 weeks (placebo 3.9%) |
| Typical combination partner | Tirzepatide (dual incretin) | Standalone triple agonist |
| Peptx availability | Factory Direct kits; UK single vials on waitlist | UK single vials and Factory Direct kits |
- Development code
- LY3841136LY3437943
- Receptor targets
- Amylin receptors (selective)GLP-1, GIP, glucagon (triple)
- Mechanism family
- Amylin analogueIncretin + glucagon agonist
- Development stage
- ENLIGHTEN Phase 3TRIUMPH Phase 3
- Peak Phase 2 body-weight reduction
- 9.5% to 20.1% at 48 weeks24.2% at 12mg by 48 weeks
- Phase 3 result
- Not yet reportedTRIUMPH-1: 17.6% to 25.0% at 80 weeks (placebo 3.9%)
- Typical combination partner
- Tirzepatide (dual incretin)Standalone triple agonist
- Peptx availability
- Factory Direct kits; UK single vials on waitlistUK single vials and Factory Direct kits
Two very different approaches to next-gen obesity pharmacology
Retatrutide's approach is receptor multi-agonism within a single molecule: keep the dual GLP-1/GIP incretin activity of Tirzepatide, then add a third arm at the glucagon receptor to drive additional adipose-mass change through hepatic pathways and thermogenesis. In Phase 2 it reached 24.2% at 48 weeks, and its Phase 3 TRIUMPH-1 trial reported up to 25.0% at 80 weeks.
Eloralintide's approach is combination rather than multi-agonism: keep the incretin backbone as a separate molecule (Tirzepatide), and pair it with a selective amylin agonist that operates on an entirely different receptor family. The bet is that non-overlapping receptor pharmacology gives you flexibility, cleaner dose-titration, and potentially better tolerability than a single-molecule triple agonist.
Which one is winning?
It is too early to tell. Retatrutide is further along: its Phase 3 TRIUMPH-1 trial, published in September 2026, reported up to 25.0% at 80 weeks. Eloralintide reached 9.5% to 20.1% on its own in Phase 2, and combined with Tirzepatide it reached 23.3% in a 2026 Phase 2b in adults with type 2 diabetes. Eloralintide's Phase 3 has not reported, and no trial has compared the two directly.
For research labs the two compounds are complementary. Retatrutide is the reference for studying receptor multi-agonism within a single molecule. Eloralintide is the reference for studying combination pharmacology across two mechanistically independent axes.
Retatrutide and Eloralintide in one vial
Retalora is a research blend of Retatrutide 10mg and Eloralintide 2.5mg in a single lyophilised vial, coming to UK Express. See Retalora.
UK single vials · Coming soon
Join the Retalora waitlist
Due in UK stock in about three to four weeks. Join the waitlist and we will email you when it lands.
Retalora 12.5mg is booked in for a full-panel independent test at Vanguard Laboratory: purity, quantity, endotoxins and sterility. Results from late October, in the COA Library.
Bottom line for research labs
For research labs modelling next-generation obesity pharmacology, both compounds are relevant but they answer different questions. Retatrutide is the reference for triple-agonist single-molecule pharmacology and has the deepest monotherapy dataset. Eloralintide is the reference for selective amylin pharmacology and combination-with-incretin research. Serious mechanism-of-action work often uses both.